IQVIA Holdings Inc. ($IQV) Stock Forecast: Up 5.0% Today

What is IQVIA Holdings Inc.?

IQVIA Holdings (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the healthcare industry.

Why is IQVIA Holdings Inc. going up?

IQV stock is up 5.0% on Feb 13, 2026 16:16

• Despite concerns about margin compression, IQVIA's Q4 earnings call exceeded revenue expectations, leading to a positive market reaction.
• Analysts remain optimistic about IQVIA's future performance, with recent insider buying and a "Moderate Buy" rating indicating confidence in the company's growth potential.
• The company's focus on AI integration, strategic acquisitions, and addressing macroeconomic challenges demonstrates its commitment to long-term success, driving the bullish movement in its stock price today.

IQV Price Chart

IQV Technical Analysis

IQV News

Charles River Labs Quarterly Resilience Faces Declining Organic Revenue Test

Charles River Laboratories (NYSE:CRL) reported resilient quarterly results despite a 2.3% average annual decline in organic revenue over the past two years, leading to a recent stock pullback. Analysts anticipate modest revenue growth and lower return on invested capital, suggesting the company relies more on cost control and execution than volume growth. Investors should monitor the company's efforts to rebuild its project pipeline and improve its return on invested capital given the current market sentiment and share price volatility.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-labs-quarterly-resilience-faces-declining-orga

The Top 5 Analyst Questions From IQVIA's Q4 Earnings Call

This article summarizes the key takeaways from IQVIA's Q4 earnings call, focusing on the five most important questions posed by analysts. While IQVIA exceeded revenue expectations, concerns about margin compression led to a negative market reaction. The company's management addressed issues related to AI integration, strategic acquisitions, and the impact of the macroeconomic environment on its performance.

https://finviz.com/news/308551/the-top-5-analyst-questions-from-iqvias-q4-earnings-call

Earnings growth of 3.6% over 3 years hasn't been enough to translate into positive returns for IQVIA Holdings (NYSE:IQV) shareholders

IQVIA Holdings (NYSE:IQV) shareholders have seen a 22% drop in share price over the past three years, significantly underperforming the market's 73% return, despite the company achieving 11% annual EPS growth during the same period. While revenue grew at a 3.7% annual rate, the discrepancy between earnings growth and share price decline suggests a potential misvaluation or other factors at play. The article recommends further investigation into IQVIA Holdings' fundamentals, noting a recent 26% share price drop after financial results, and suggests looking for insider buying as a positive sign.

https://finance.yahoo.com/news/earnings-growth-3-6-over-110022239.html

75,170 Shares in IQVIA Holdings Inc. $IQV Purchased by Eubel Brady & Suttman Asset Management Inc.

Eubel Brady & Suttman Asset Management Inc. recently acquired 75,170 shares of IQVIA Holdings Inc. (NYSE:IQV), valued at approximately $14.28 million, making it their 26th largest holding. Despite several recent price target reductions, analysts maintain a "Moderate Buy" rating with a consensus price target of $238.20 for IQVIA. The medical research company reported strong Q3 earnings, beating consensus estimates for both EPS and revenue, and provided optimistic FY2026 EPS guidance.

https://www.marketbeat.com/instant-alerts/filing-75170-shares-in-iqvia-holdings-inc-iqv-purchased-by-eubel-brady-suttman-asset-management-inc-2026-02-12/

The Clinical Crisis: A Deep-Dive Into ICON plc (ICLR) Amidst a Transformational Storm

ICON plc (ICLR), the second-largest Clinical Research Organization, is facing a crisis due to an internal accounting investigation revealing revenue recognition errors from 2023-2025, leading to a significant stock price decline. Despite this, the company's operational engine, AI tools, and substantial backlog remain strong, positioning it as a high-risk, high-reward investment opportunity ahead of its April 30, 2026, restatement deadline.

https://markets.financialcontent.com/wral/article/finterra-2026-2-12-the-clinical-crisis-a-deep-dive-into-icon-plc-iclr-amidst-a-transformational-storm

Trending Today

Uniswap ($UNI) Crypto Forecast: Up 6.3% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 5.4% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 31.3% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Up 6.1% Today

Fiverr International Ltd. ($FVRR) Stock Forecast: Up 5.1% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 5.3% Today

Etsy Inc. ($ETSY) Stock Forecast: Up 9.8% Today

Corning Incorporated ($GLW) Stock Forecast: Up 5.8% Today

Chemours Company (The) ($CC) Stock Forecast: Down 18.3% Today

Oracle Corporation ($ORCL) Stock Forecast: Down 5.2% Today

IQVIA Holdings Inc. Price History

13.01.2026 - IQV Stock was up 5.0%

• Despite concerns about margin compression, IQVIA's Q4 earnings call exceeded revenue expectations, leading to a positive market reaction.
• Analysts remain optimistic about IQVIA's future performance, with recent insider buying and a "Moderate Buy" rating indicating confidence in the company's growth potential.
• The company's focus on AI integration, strategic acquisitions, and addressing macroeconomic challenges demonstrates its commitment to long-term success, driving the bullish movement in its stock price today.

05.01.2026 - IQV Stock was down 6.6%

• Despite exceeding earnings forecasts and providing optimistic guidance for 2026, IQV's stock experienced a significant drop of 9.02% in pre-market trading.
• The market's reaction to IQV's strong financial performance could be attributed to broader market dynamics and concerns about the disruptive potential of AI technologies.
• While IQV showcased robust profitability and growth, the high debt-to-equity ratio and potential liquidity challenges highlighted in the analysis might have contributed to the bearish movement in the stock.
• CEO Ari Bousbib's emphasis on AI as a positive enabler for IQVIA's business, along with strategic acquisitions and AI advancements, could be key factors to monitor for potential market recovery.

05.01.2026 - IQV Stock was down 7.6%

• Despite strong financial performance in the fourth quarter, surpassing revenue projections, IQV encountered a downward trend in the market.
• The market decline may stem from concerns surrounding the company's high debt-to-equity ratio and potential liquidity issues, possibly overshadowing the positive financial results.
• Moreover, comparisons depicting IQV as a more attractive investment choice than Idexx Laboratories could have impacted investor confidence, leading to profit-taking or a shift in investment strategies.
• Investors appear wary leading up to the upcoming earnings release, seeking clarity on margin growth and new enterprise partnerships, particularly within the Technology & Analytics Solutions sector, amid budget constraints in the biotech industry.

20.00.2026 - IQV Stock was up 1.8%

• IQV's bullish movement can be attributed to its strong financial performance, technical indicators, and analyst confidence, indicating a promising investment opportunity.
• The increased stake by an investment firm and the company's strong Q3 earnings, beating analyst expectations, likely contributed to the positive market movement.
• Additionally, the overall rebound in the healthcare sector, driven by increased clarity on drug pricing and tariffs, may have further boosted IQV's performance as a top pick for investors in 2026.
• The company's current trading above key moving averages and consensus "Moderate Buy" rating with an average target price near $249.19 reinforce the bullish outlook for IQV.

12.01.2026 - IQV Stock was down 8.4%

• Amid Q3 earnings strength and upbeat FY2026 guidance, IQVIA Holdings Inc. (IQV) witnessed bearish movement likely attributed to:
• Decline in share price over three years, suggesting potential misvaluation or market influences.
• A recent 26% share price plunge after financial results release, causing investor apprehension.
• Price target cuts by analysts while maintaining a "Moderate Buy" rating, reflecting market uncertainty.
• Share price drop on February 10, indicating short-term selling pressure and market volatility.

12.01.2026 - IQV Stock was down 8.3%

• Despite strong Q3 earnings and positive FY2026 guidance, IQVIA Holdings' stock dropped by 26% post-financial results, indicating investor concerns.
• The discrepancy between the company's 11% annual EPS growth and the 22% decline in share price over a three-year period suggests potential misvaluation or underlying issues impacting investor sentiment.
• The recent acquisition of a significant number of IQVIA shares by Eubel Brady & Suttman Asset Management Inc. may indicate confidence in the company's long-term prospects, though market sentiment remains cautious.
• The overall bearish trend in IQV's stock could be linked to broader challenges in the medical research sector, illustrated by negative trends in competitors such as ICON plc and Charles River Laboratories International, influencing investor sentiment industry-wide.

11.01.2026 - IQV Stock was down 5.0%

• IQVIA stock saw significant downward movement during the trading day.
• The collaboration between IQVIA and the Duke Clinical Research Institute aimed at advancing clinical research in obesity and related conditions was well-received by investors.
• Despite the upbeat response to the research partnership, the stock's decline may be linked to a decrease in ownership by Compagnie Lombard Odier SCmA, suggesting waning confidence from some institutional investors.
• The overall market outlook for IQVIA is optimistic, with analysts upholding a "Moderate Buy" consensus rating and an average price target of $239.87, indicating potential growth despite today's market performance.

04.01.2026 - IQV Stock was down 13.6%

• IQV's stock price fell by 9.18% on February 3rd, closing at $210.00.
• Investor caution and profit-taking prior to the upcoming Q4 earnings report on February 5th likely contributed to this decline.
• Despite the recent drop, analysts are optimistic about IQV's future, suggesting potential for significant growth and indicating that short-term fluctuations may be causing an overreaction in the market.
• IQV's stock underperformance relative to industry competitors and broader market indices hints at broader market sentiment and sector-specific influences impacting the bearish movement.

10.01.2026 - IQV Stock was down 5.2%

• A strategic collaboration with the Duke Clinical Research Institute to advance clinical research in obesity and related conditions is expected to have a positive impact on the company's growth and its influence on patient therapies.
• The recent reduction in stake by Compagnie Lombard Odier SCmA and Thrivent Financial for Lutherans could have contributed to a bearish movement in the stock, potentially indicating profit-taking or a shift in investor sentiment.
• Despite surpassing earnings and revenue expectations in the last quarter and offering optimistic guidance for FY 2026, concerns regarding increased interest expenses and lowered price targets by analysts may have impacted the stock's performance.
• The general market sentiment towards IQVIA is cautiously optimistic, with a consensus rating of "Moderate Buy" and an average target price of $239.87, suggesting potential for recovery ahead.

03.01.2026 - IQV Stock was down 9.4%

• IQV experienced a bearish movement likely due to:
• Analysts' cautious outlook on the company's Q4 earnings despite a history of positive surprises.
• Institutional investors adjusting their positions, with Running Oak Capital LLC selling shares and others increasing stakes, possibly signaling mixed sentiments in the market.
• The broader market reaction to another company's decline post-earnings beat, indicating sector-wide concerns over future guidance and valuation.
• The AI-generated analysis pointing to weak near and mid-term sentiment, contributing to the negative market movement for IQV.

03.01.2026 - IQV Stock was down 2.6%

• Running Oak Capital LLC reduced its stake in IQVIA during Q3, which might have signaled a lack of confidence in the company's future prospects, contributing to the bearish movement.
• Despite positive earnings reported by Thermo Fisher Scientific, concerns over academic and government spending, leadership changes, and elevated valuation in the sector led to a broader decline, potentially impacting IQVIA's stock negatively.
• The increase in institutional ownership, as seen with Nichols & Pratt Advisers LLP MA and Mediolanum International Funds Ltd, could indicate a positive sentiment towards IQVIA, but the overall market sentiment might have overshadowed these individual moves, resulting in the bearish trend.
• The bullish market movement in the Pharmacoeconomics industry, with major players like IQVIA being highlighted, could suggest long-term growth potential for the sector, despite the short-term bearish movement in IQV's stock.

06.01.2026 - IQV Stock was up 5.4%

• Despite adjustments in price targets by various analysts, IQVIA Holdings (IQV) witnessed significant bullish movement in the market today.
• The market is responding positively to IQVIA's robust performance in Q4 2025, surpassing revenue projections and demonstrating a commitment to AI-driven solutions for future expansion.
• Analysts' concerns regarding margin pressures and sustainability of growth have been somewhat overshadowed by the company's strategic acquisitions, streamlined business operations, and optimistic 2026 forecast.
• Investors appear to find IQVIA Holdings' current valuation appealing for potential growth opportunities, despite short-term challenges highlighted by analysts.